1. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? 
G.L. Daikos, A. Markogiannakis 
Clinical Microbiology and Infection 
Volume 17, Issue 8, Pages (August 2011)
DOI: /j x
Copyright © 2011 European Society of Clinical Infectious Diseases Terms and Conditions

2. FIG. 1
Simulated concentration–time profiles of three different dosing regimens of meropenem. TI, traditional 30-min infusion; PI, prolonged 3-h infusion. Adapted from [35,45,47].
Clinical Microbiology and Infection  , DOI: ( /j x)
Copyright © 2011 European Society of Clinical Infectious Diseases Terms and Conditions

3. FIG. 2
Simulated target attainment probabilities for 50% time above the MIC (50% T > MIC) of three different regiments of meropenem. TI, traditional 30-min infusion; PI, prolonged 3-h infusion. Adapted from [36].
Clinical Microbiology and Infection  , DOI: ( /j x)
Copyright © 2011 European Society of Clinical Infectious Diseases Terms and Conditions